<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01358578</url>
  </required_header>
  <id_info>
    <org_study_id>CAIN457A2303</org_study_id>
    <secondary_id>2010-022228-66</secondary_id>
    <nct_id>NCT01358578</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis</brief_title>
  <acronym>FIXTURE</acronym>
  <official_title>A Randomized, Double-blind, Double-dummy, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, Compared to Placebo and Etanercept, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and efficacy of secukinumab compared to placebo and
      etanercept in patients that have moderate to severe, chronic, plaque-type psoriasis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Secukinumab Compared to Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure: PASI 75 (Psoriasis Area and Severity Index) .</measure>
    <time_frame>12 wks</time_frame>
    <description>A 75% reduction in the Psoriasis Area and Severity Index (PASI) score (PASI 75) is the current benchmark of primary endpoints for most clinical trials of psoriasis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of Secukinumab Compared to Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure:IGA (Investigator's Global Assessment) Mod 2011 With a 0 or 1 Response at Week 12</measure>
    <time_frame>12 wks</time_frame>
    <description>The IGA mod 2011 scale has been developed based on a previous version of the scale used in secukinumab phase II studies in collaboration with health authorities, in particular the FDA. The explanations/descriptions of the points on the scale have been improved to ensure appropriate differentiation between the points. The IGA mod 2011 used in this study is static, i.e. it refers exclusively to the subject's disease state at the time of the assessments, and does not attempt a comparison with any of the subject's previous disease states, whether at baseline or at a previous visit.IGA mod 2011 has a scale of 0-4 with the lower scores correlating to better performance. A score of 0= clear skin, 1= almost clear skin, 2=mild, 3=moderate,4=severe.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of Secukinumab Compared to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure: PASI 90 at Week 12</measure>
    <time_frame>12 wks</time_frame>
    <description>A 90% reduction in the Psoriasis Area and Severity Index (PASI) score (PASI 90) is above current benchmark of primary endpoints for most clinical trials of psoriasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure: PASI 75 at Week 12</measure>
    <time_frame>12 wks</time_frame>
    <description>A 75% reduction in the Psoriasis Area and Severity Index (PASI) score (PASI 75) is the current benchmark of primary endpoints for most clinical trials of psoriasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure: :IGA (Investigator's Global Assessment) Mod 2011 With a 0 or 1 Response at Week 12</measure>
    <time_frame>12 wks</time_frame>
    <description>The IGA mod 2011 scale has been developed based on a previous version of the scale used in secukinumab phase II studies in collaboration with health authorities, in particular the FDA. The explanations/descriptions of the points on the scale have been improved to ensure appropriate differentiation between the points. The IGA mod 2011 used in this study is static, i.e. it refers exclusively to the subject's disease state at the time of the assessments, and does not attempt a comparison with any of the subject's previous disease states, whether at baseline or at a previous visit.IGA mod 2011 has a scale of 0-4 with the lower scores correlating to better performance. A score of 0= clear skin, 1= almost clear skin, 2=mild, 3=moderate,4=severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance of PASI 75 Response at Week 52 for Patients Who Were PASI 75 Responders at Week 12 (Non-responder Imputation)</measure>
    <time_frame>52 wks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance of IGA Mod 2011 0 or 1 Response After 52 Weeks of Treatment for Subjects Who Were IGA Mod 2011 0 or 1 Responders After 12 Weeks of Treatment</measure>
    <time_frame>52 wks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Score From Baseline to Week 12 in Psoriasis Symptom Diary Items Itching, Pain and Scaling in AIN457 vs Placebo</measure>
    <time_frame>baseline to week 12</time_frame>
    <description>The Psoriasis Symptom Diary©, a 16-item patient reported outcome (PRO) measure developed and validated in accordance with the FDA PRO Guidance (FDA Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims, 2009), demonstrated favorable psychometric properties and usefulness for treatment efficacy evaluation alongside other measures of disease severity in clinical trials for chronic plaque psoriasis.Weekly averages will be derived for each of the 16 questions of the Psoriasis Diary up to Week 12. A weekly average is the sum of the scored item over the course of the study week divided by the number of days on which the item was completed and will be set to missing if four or more daily assessments were missing of the corresponding question. The range for each question is 0 to 10 with the higher score depicting a more progressed disease state. A reduction in score from baseline shows efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in Psoriasis Symptom Diary Items Itching, Pain and Scaling in AIN457 vs Etanercept</measure>
    <time_frame>baseline to week 12</time_frame>
    <description>The Psoriasis Symptom Diary©, a 16-item patient reported outcome (PRO) measure developed and validated in accordance with the FDA PRO Guidance (FDA Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims, 2009), demonstrated favorable psychometric properties and usefulness for treatment efficacy evaluation alongside other measures of disease severity in clinical trials for chronic plaque psoriasis.Weekly averages will be derived for each of the 16 questions of the Psoriasis Diary up to Week 12. A weekly average is the sum of the scored item over the course of the study week divided by the number of days on which the item was completed and will be set to missing if four or more daily assessments were missing of the corresponding question. The range for each question is 0 to 10 with the higher score depicting a more progressed disease state. A reduction in score from baseline shows efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Developing Anti-secukinumab Antibodies</measure>
    <time_frame>60 weeks</time_frame>
    <description>Describes the number of participants tested positive for anti-secukinumab antibodies. It refers to the number of patients who had no positive values at baseline but developed them only after start of active study treatment (AIN457 or etanercept)</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">1306</enrollment>
  <condition>Chronic Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>AIN457 150mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AIN457 150mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AIN457 300mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AIN457 300mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etanercept</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Etanercept</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AIN457 150mg from Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to AIN457 150mg in Maintenance phase when they were on Placebo in Induction Phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AIN457 300mg from Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to AIN457 300mg in Maintenance phase when they were on Placebo in Induction Phase</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to Match secukinumab (AIN457) 150mg or 300mg or Placebo to match etanercept</description>
    <arm_group_label>AIN457 150mg</arm_group_label>
    <arm_group_label>AIN457 300mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Etanercept</arm_group_label>
    <arm_group_label>AIN457 150mg from Placebo</arm_group_label>
    <arm_group_label>AIN457 300mg from Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>secukinumab (AIN457)</intervention_name>
    <description>secukinumab (AIN457) 150mg or 300mg subcutaneous</description>
    <arm_group_label>AIN457 150mg</arm_group_label>
    <arm_group_label>AIN457 300mg</arm_group_label>
    <arm_group_label>AIN457 150mg from Placebo</arm_group_label>
    <arm_group_label>AIN457 300mg from Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etanercept</intervention_name>
    <description>etanercept 50mg subcutaneous</description>
    <arm_group_label>Etanercept</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with chronic, plaque-type psoriasis for at least 6 months

          -  Must have moderate to severe psoriasis based on PASI greater than 12, IGA greater than
             3, and greater than 10% body surface area

          -  Must be inadequately controlled by prior treatments (topicals, phototherapy, and/or
             systemic therapies)

        Exclusion Criteria:

          -  Forms of psoriasis other than chronic, plaque-type (such as pustular, erythrodermic
             and guttate psoriasis)

          -  Drug induced psoriasis

          -  Use of other psoriasis treatments during the study

          -  Prior use of etanercept

          -  Prior use of secukinumab or any other drug that target IL-17 (interleukin 17) or the
             IL-17 receptor

          -  Pregnant or lactating women; women who do not agree to use contraception during the
             study and for 16 weeks after stopping treatment

          -  Significant medical problems such as uncontrolled high blood pressure, congestive
             heart failure, etc.

          -  History of an ongoing, chronic or recurrent infection or evidence of tuberculosis

          -  Allergy to rubber or latex

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warren</city>
        <state>Ohio</state>
        <zip>44483</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Johnston</city>
        <state>Rhode Island</state>
        <zip>02919</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1062ABK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1114AAO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1181ACH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1425BEI</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Capital Federal</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1425DKG</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mendoza</city>
        <zip>M5502EZA</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Carlton</city>
        <state>Victoria</state>
        <zip>3053</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5K 1X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V 0C6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Richmond Hil</city>
        <state>Ontario</state>
        <zip>L4B 1A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <zip>G1V 4X7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bogotá</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bucaramanga</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alexandria</city>
        <zip>21131</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00250</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Turku</city>
        <zip>FIN-20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marseille Cedex 9</city>
        <zip>13913</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Martigues</city>
        <zip>13500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nice Cedex 3</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pessac Cedex</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toulouse Cedex</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Augsburg</city>
        <zip>86179</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10827</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13187</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bielefeld</city>
        <zip>33647</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bochum</city>
        <zip>44803</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Darmstadt</city>
        <zip>64283</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erfurt</city>
        <zip>99089</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erlangen</city>
        <zip>91052</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gera</city>
        <zip>07548</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Goettingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Greifswald</city>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20354</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22143</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22391</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hanau</city>
        <zip>63450</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Krefeld</city>
        <zip>47805</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>München</city>
        <zip>80802</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nuernberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osnabrück</city>
        <zip>49074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plauen</city>
        <zip>08529</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Recklinghausen</city>
        <zip>45657</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Schwerin</city>
        <zip>19055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Witten</city>
        <zip>58452</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wuppertal</city>
        <zip>42275</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guatemala City</city>
        <zip>01010</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guatemala City</city>
        <zip>01015</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1134</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaposvár</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miskolc</city>
        <zip>3529</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szeged</city>
        <zip>H-6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szombathely</city>
        <zip>9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kopavogur</city>
        <zip>IS-201</zip>
        <country>Iceland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vishakhapatnam</city>
        <state>Andhra Pradesh</state>
        <zip>532 002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>400038</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mangalore</city>
        <state>Karnataka</state>
        <zip>575002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dadar (east) mumbai</city>
        <state>Maharashtra</state>
        <zip>400018</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400 022</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440019</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dehli</city>
        <state>New Delhi</state>
        <zip>110 051</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hyderabad</city>
        <zip>500044</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>L'Aquila</city>
        <state>AQ</state>
        <zip>67100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Catania</city>
        <state>CT</state>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Terracina</city>
        <state>LT</state>
        <zip>04019</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Modena</city>
        <state>MO</state>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00167</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Anyang</city>
        <state>Gyeonggi-do</state>
        <zip>431-070</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Busan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Daejeon</city>
        <zip>301-747</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gwangju</city>
        <zip>501-575</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>143-729</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>156-755</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>738-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Las Pinas</city>
        <zip>1740</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manila</city>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lodz</city>
        <zip>90-265</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lodz</city>
        <zip>90-436</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poznan</city>
        <zip>60-529</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-368</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bucuresti</city>
        <zip>011461</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bucuresti</city>
        <zip>021105</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bucuresti</city>
        <zip>041335</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bucuresti</city>
        <zip>062272</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santa Coloma de Gramanet</city>
        <state>Cataluña</state>
        <zip>08923</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28031</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Göteborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Luleå</city>
        <zip>972 33</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Malmo</city>
        <zip>SE-205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plymouth</city>
        <state>Devon</state>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salford</city>
        <state>Manchester</state>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yeovil</city>
        <state>Somerset</state>
        <zip>BA21 4AT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dudley</city>
        <zip>DY1 2HQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Harrogate</city>
        <zip>HG2 7SX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>E11 1NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nuneaton</city>
        <zip>CV10 7DJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Egypt</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Guatemala</country>
    <country>Hungary</country>
    <country>Iceland</country>
    <country>India</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Russian Federation</country>
    <country>Turkey</country>
  </removed_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2011</study_first_submitted>
  <study_first_submitted_qc>May 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2011</study_first_posted>
  <results_first_submitted>February 16, 2015</results_first_submitted>
  <results_first_submitted_qc>August 20, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 23, 2015</results_first_posted>
  <last_update_submitted>January 19, 2016</last_update_submitted>
  <last_update_submitted_qc>January 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis,</keyword>
  <keyword>inflammatory skin disease,</keyword>
  <keyword>scaly patches</keyword>
  <keyword>Psoriasis</keyword>
  <keyword>inflammatory skin disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AIN457 150mg</title>
          <description>s.c. secukinumab 150 mg injection plus a placebo secukinumab injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48</description>
        </group>
        <group group_id="P2">
          <title>AIN457 300mg</title>
          <description>s.c. secukinumab 300 mg injection plus a placebo secukinumab injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>s.c. placebo etanercept twice per week until Week 12 and s.c. placebo secukinumab (2 injections per dose) once per week for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks (at Weeks 4 and 8). Prior to receiving the Week 12 dose, all patients in the placebo group were assigned to the following treatment groups based on their PASI 75 response status at Week 12:</description>
        </group>
        <group group_id="P4">
          <title>Etanercept</title>
          <description>Subcutaneous (s.c.) etanercept 50 mg twice per week until Week 12, followed by s.c. etanercept 50 mg every week from Week 12 through Week 51. To maintain the blind, patients also received 2 placebo secukinumab s.c.
injections once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48, except for Weeks 13, 14, and 15 where patients received an additional weekly dose (comprised of 2 s.c. injections per dose) of placebo secukinumab.</description>
        </group>
        <group group_id="P5">
          <title>AIN457 150mg From Placebo</title>
          <description>Patients were on Placebo in induction phase and if they were PASI 75 non responders at week 12 were re randomized to AIN457 150 in maintenance</description>
        </group>
        <group group_id="P6">
          <title>AIN457 300mg From Placebo</title>
          <description>Patients were on Placebo in induction phase and if they were PASI 75 non responders at week 12 were re randomized to AIN457 300 in maintenance</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Induction Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="327"/>
                <participants group_id="P2" count="327"/>
                <participants group_id="P3" count="326"/>
                <participants group_id="P4" count="326"/>
                <participants group_id="P5" count="0">These groups are populated after the induction period</participants>
                <participants group_id="P6" count="0">These groups are populated after the induction period</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="315"/>
                <participants group_id="P2" count="312"/>
                <participants group_id="P3" count="301"/>
                <participants group_id="P4" count="305"/>
                <participants group_id="P5" count="0">These groups are populated after the induction period</participants>
                <participants group_id="P6" count="0">These groups are populated after the induction period</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="21"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>technical problems</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Maintenance Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="315"/>
                <participants group_id="P2" count="312"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="305"/>
                <participants group_id="P5" count="142"/>
                <participants group_id="P6" count="142"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="276"/>
                <participants group_id="P2" count="290"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="263"/>
                <participants group_id="P5" count="125"/>
                <participants group_id="P6" count="131"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="42"/>
                <participants group_id="P5" count="17"/>
                <participants group_id="P6" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with study treatment</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow-up Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="148">Patients prior to follow up who did not enter the extension study but received the 150 mg dose</participants>
                <participants group_id="P2" count="125">Patients prior to follow up who did not enter the extension study but received the 300 mg dose</participants>
                <participants group_id="P3" count="26">contains patients who participated in follow up period from induction and maintenance</participants>
                <participants group_id="P4" count="279">contains patients who participated in follow up period from induction and maintenance</participants>
                <participants group_id="P5" count="0">all placebo patients from induction were 1: 1 into either AIN457A 150 mg or 300 mg doses</participants>
                <participants group_id="P6" count="0">all placebo patients from induction were 1: 1 into either AIN457A 150 mg or 300 mg doses</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="138"/>
                <participants group_id="P2" count="119"/>
                <participants group_id="P3" count="21">contains patients who completed follow up period from induction and maintenance</participants>
                <participants group_id="P4" count="260">contains patients who completed follow up period from induction and maintenance</participants>
                <participants group_id="P5" count="0">all placebo patients from induction were 1: 1 into either AIN457A 150 mg or 300 mg doses</participants>
                <participants group_id="P6" count="0">all placebo patients from induction were 1: 1 into either AIN457A 150 mg or 300 mg doses</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="19"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>non- compliance with study treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AIN457 150mg</title>
          <description>AIN457 150mg</description>
        </group>
        <group group_id="B2">
          <title>AIN457 300mg</title>
          <description>AIN457 300mg</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="B4">
          <title>Etanercept</title>
          <description>Etanercept</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="327"/>
            <count group_id="B2" value="327"/>
            <count group_id="B3" value="326"/>
            <count group_id="B4" value="326"/>
            <count group_id="B5" value="1306"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="304"/>
                    <measurement group_id="B2" value="305"/>
                    <measurement group_id="B3" value="311"/>
                    <measurement group_id="B4" value="308"/>
                    <measurement group_id="B5" value="1228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.4" spread="12.92"/>
                    <measurement group_id="B2" value="44.5" spread="13.19"/>
                    <measurement group_id="B3" value="44.1" spread="12.64"/>
                    <measurement group_id="B4" value="43.8" spread="12.95"/>
                    <measurement group_id="B5" value="44.4" spread="12.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="89"/>
                    <measurement group_id="B4" value="94"/>
                    <measurement group_id="B5" value="377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="236"/>
                    <measurement group_id="B2" value="224"/>
                    <measurement group_id="B3" value="237"/>
                    <measurement group_id="B4" value="232"/>
                    <measurement group_id="B5" value="929"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="72"/>
                    <measurement group_id="B4" value="74"/>
                    <measurement group_id="B5" value="291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="219"/>
                    <measurement group_id="B2" value="224"/>
                    <measurement group_id="B3" value="218"/>
                    <measurement group_id="B4" value="219"/>
                    <measurement group_id="B5" value="880"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy of Secukinumab Compared to Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure: PASI 75 (Psoriasis Area and Severity Index) .</title>
        <description>A 75% reduction in the Psoriasis Area and Severity Index (PASI) score (PASI 75) is the current benchmark of primary endpoints for most clinical trials of psoriasis</description>
        <time_frame>12 wks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150mg</title>
            <description>s.c. secukinumab 150 mg injection plus a placebo secukinumab injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300mg</title>
            <description>s.c. secukinumab 300 mg injection plus a placebo secukinumab injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>s.c. placebo etanercept twice per week until Week 12 and s.c. placebo secukinumab (2 injections per dose) once per week for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks (at Weeks 4 and 8). Prior to receiving the Week 12 dose, all patients in the placebo group were assigned to the following treatment groups based on their PASI 75 response status at Week 12:</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of Secukinumab Compared to Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure: PASI 75 (Psoriasis Area and Severity Index) .</title>
          <description>A 75% reduction in the Psoriasis Area and Severity Index (PASI) score (PASI 75) is the current benchmark of primary endpoints for most clinical trials of psoriasis</description>
          <units>participants achieving goal</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="327"/>
                <count group_id="O2" value="323"/>
                <count group_id="O3" value="324"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219"/>
                    <measurement group_id="O2" value="249"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy of Secukinumab Compared to Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure:IGA (Investigator’s Global Assessment) Mod 2011 With a 0 or 1 Response at Week 12</title>
        <description>The IGA mod 2011 scale has been developed based on a previous version of the scale used in secukinumab phase II studies in collaboration with health authorities, in particular the FDA. The explanations/descriptions of the points on the scale have been improved to ensure appropriate differentiation between the points. The IGA mod 2011 used in this study is static, i.e. it refers exclusively to the subject’s disease state at the time of the assessments, and does not attempt a comparison with any of the subject’s previous disease states, whether at baseline or at a previous visit.IGA mod 2011 has a scale of 0-4 with the lower scores correlating to better performance. A score of 0= clear skin, 1= almost clear skin, 2=mild, 3=moderate,4=severe.</description>
        <time_frame>12 wks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150mg</title>
            <description>s.c. secukinumab 150 mg injection plus a placebo secukinumab injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300mg</title>
            <description>s.c. secukinumab 300 mg injection plus a placebo secukinumab injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>s.c. placebo etanercept twice per week until Week 12 and s.c. placebo secukinumab (2 injections per dose) once per week for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks (at Weeks 4 and 8). Prior to receiving the Week 12 dose, all patients in the placebo group were assigned to the following treatment groups based on their PASI 75 response status at Week 12:</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of Secukinumab Compared to Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure:IGA (Investigator’s Global Assessment) Mod 2011 With a 0 or 1 Response at Week 12</title>
          <description>The IGA mod 2011 scale has been developed based on a previous version of the scale used in secukinumab phase II studies in collaboration with health authorities, in particular the FDA. The explanations/descriptions of the points on the scale have been improved to ensure appropriate differentiation between the points. The IGA mod 2011 used in this study is static, i.e. it refers exclusively to the subject’s disease state at the time of the assessments, and does not attempt a comparison with any of the subject’s previous disease states, whether at baseline or at a previous visit.IGA mod 2011 has a scale of 0-4 with the lower scores correlating to better performance. A score of 0= clear skin, 1= almost clear skin, 2=mild, 3=moderate,4=severe.</description>
          <units>participants acheiving goal</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="327"/>
                <count group_id="O2" value="323"/>
                <count group_id="O3" value="324"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167"/>
                    <measurement group_id="O2" value="202"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy of Secukinumab Compared to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure: PASI 90 at Week 12</title>
        <description>A 90% reduction in the Psoriasis Area and Severity Index (PASI) score (PASI 90) is above current benchmark of primary endpoints for most clinical trials of psoriasis</description>
        <time_frame>12 wks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150mg</title>
            <description>s.c. secukinumab 150 mg injection plus a placebo secukinumab injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300mg</title>
            <description>s.c. secukinumab 300 mg injection plus a placebo secukinumab injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48</description>
          </group>
          <group group_id="O3">
            <title>Etanercept</title>
            <description>Subcutaneous (s.c.) etanercept 50 mg twice per week until Week 12, followed by s.c. etanercept 50 mg every week from Week 12 through Week 51. To maintain the blind, patients also received 2 placebo secukinumab s.c.
injections once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48, except for Weeks 13, 14, and 15 where patients received an additional weekly dose (comprised of 2 s.c. injections per dose) of placebo secukinumab.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>s.c. placebo etanercept twice per week until Week 12 and s.c. placebo secukinumab (2 injections per dose) once per week for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks (at Weeks 4 and 8). Prior to receiving the Week 12 dose, all patients in the placebo group were assigned to the following treatment groups based on their PASI 75 response status at Week 12:</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of Secukinumab Compared to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure: PASI 90 at Week 12</title>
          <description>A 90% reduction in the Psoriasis Area and Severity Index (PASI) score (PASI 90) is above current benchmark of primary endpoints for most clinical trials of psoriasis</description>
          <population>FAS</population>
          <units>participant who acheived goal</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="327"/>
                <count group_id="O2" value="323"/>
                <count group_id="O3" value="323"/>
                <count group_id="O4" value="324"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137"/>
                    <measurement group_id="O2" value="175"/>
                    <measurement group_id="O3" value="67"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure: PASI 75 at Week 12</title>
        <description>A 75% reduction in the Psoriasis Area and Severity Index (PASI) score (PASI 75) is the current benchmark of primary endpoints for most clinical trials of psoriasis</description>
        <time_frame>12 wks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150mg</title>
            <description>s.c. secukinumab 150 mg injection plus a placebo secukinumab injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300mg</title>
            <description>s.c. secukinumab 300 mg injection plus a placebo secukinumab injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48</description>
          </group>
          <group group_id="O3">
            <title>Etanercept</title>
            <description>Subcutaneous (s.c.) etanercept 50 mg twice per week until Week 12, followed by s.c. etanercept 50 mg every week from Week 12 through Week 51. To maintain the blind, patients also received 2 placebo secukinumab s.c. injections once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48, except for Weeks 13, 14, and 15 where patients received an additional weekly dose (comprised of 2 s.c. injections per dose) of placebo secukinumab.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure: PASI 75 at Week 12</title>
          <description>A 75% reduction in the Psoriasis Area and Severity Index (PASI) score (PASI 75) is the current benchmark of primary endpoints for most clinical trials of psoriasis</description>
          <population>FAS</population>
          <units>participant who acheived goal</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="327"/>
                <count group_id="O2" value="323"/>
                <count group_id="O3" value="323"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219"/>
                    <measurement group_id="O2" value="249"/>
                    <measurement group_id="O3" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure: :IGA (Investigator’s Global Assessment) Mod 2011 With a 0 or 1 Response at Week 12</title>
        <description>The IGA mod 2011 scale has been developed based on a previous version of the scale used in secukinumab phase II studies in collaboration with health authorities, in particular the FDA. The explanations/descriptions of the points on the scale have been improved to ensure appropriate differentiation between the points. The IGA mod 2011 used in this study is static, i.e. it refers exclusively to the subject’s disease state at the time of the assessments, and does not attempt a comparison with any of the subject’s previous disease states, whether at baseline or at a previous visit.IGA mod 2011 has a scale of 0-4 with the lower scores correlating to better performance. A score of 0= clear skin, 1= almost clear skin, 2=mild, 3=moderate,4=severe.</description>
        <time_frame>12 wks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150mg</title>
            <description>s.c. secukinumab 150 mg injection plus a placebo secukinumab injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300mg</title>
            <description>s.c. secukinumab 300 mg injection plus a placebo secukinumab injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48</description>
          </group>
          <group group_id="O3">
            <title>Etanercept</title>
            <description>Subcutaneous (s.c.) etanercept 50 mg twice per week until Week 12, followed by s.c. etanercept 50 mg every week from Week 12 through Week 51. To maintain the blind, patients also received 2 placebo secukinumab s.c. injections once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48, except for Weeks 13, 14, and 15 where patients received an additional weekly dose (comprised of 2 s.c. injections per dose) of placebo secukinumab.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure: :IGA (Investigator’s Global Assessment) Mod 2011 With a 0 or 1 Response at Week 12</title>
          <description>The IGA mod 2011 scale has been developed based on a previous version of the scale used in secukinumab phase II studies in collaboration with health authorities, in particular the FDA. The explanations/descriptions of the points on the scale have been improved to ensure appropriate differentiation between the points. The IGA mod 2011 used in this study is static, i.e. it refers exclusively to the subject’s disease state at the time of the assessments, and does not attempt a comparison with any of the subject’s previous disease states, whether at baseline or at a previous visit.IGA mod 2011 has a scale of 0-4 with the lower scores correlating to better performance. A score of 0= clear skin, 1= almost clear skin, 2=mild, 3=moderate,4=severe.</description>
          <population>FAS</population>
          <units>participant acheiving goal</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="327"/>
                <count group_id="O2" value="323"/>
                <count group_id="O3" value="323"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167"/>
                    <measurement group_id="O2" value="202"/>
                    <measurement group_id="O3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maintenance of PASI 75 Response at Week 52 for Patients Who Were PASI 75 Responders at Week 12 (Non-responder Imputation)</title>
        <time_frame>52 wks</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150mg</title>
            <description>s.c. secukinumab 150 mg injection plus a placebo secukinumab injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300mg</title>
            <description>s.c. secukinumab 300 mg injection plus a placebo secukinumab injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48</description>
          </group>
          <group group_id="O3">
            <title>Etanercept</title>
            <description>Subcutaneous (s.c.) etanercept 50 mg twice per week until Week 12, followed by s.c. etanercept 50 mg every week from Week 12 through Week 51. To maintain the blind, patients also received 2 placebo secukinumab s.c. injections once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48, except for Weeks 13, 14, and 15 where patients received an additional weekly dose (comprised of 2 s.c. injections per dose) of placebo secukinumab.</description>
          </group>
        </group_list>
        <measure>
          <title>Maintenance of PASI 75 Response at Week 52 for Patients Who Were PASI 75 Responders at Week 12 (Non-responder Imputation)</title>
          <population>Full analysis set</population>
          <units>participants who reached goal</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="249"/>
                <count group_id="O3" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180"/>
                    <measurement group_id="O2" value="210"/>
                    <measurement group_id="O3" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maintenance of IGA Mod 2011 0 or 1 Response After 52 Weeks of Treatment for Subjects Who Were IGA Mod 2011 0 or 1 Responders After 12 Weeks of Treatment</title>
        <time_frame>52 wks</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150mg</title>
            <description>s.c. secukinumab 150 mg injection plus a placebo secukinumab injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300mg</title>
            <description>s.c. secukinumab 300 mg injection plus a placebo secukinumab injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48</description>
          </group>
          <group group_id="O3">
            <title>Etanercept</title>
            <description>Subcutaneous (s.c.) etanercept 50 mg twice per week until Week 12, followed by s.c. etanercept 50 mg every week from Week 12 through Week 51. To maintain the blind, patients also received 2 placebo secukinumab s.c. injections once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48, except for Weeks 13, 14, and 15 where patients received an additional weekly dose (comprised of 2 s.c. injections per dose) of placebo secukinumab.</description>
          </group>
        </group_list>
        <measure>
          <title>Maintenance of IGA Mod 2011 0 or 1 Response After 52 Weeks of Treatment for Subjects Who Were IGA Mod 2011 0 or 1 Responders After 12 Weeks of Treatment</title>
          <population>Full analysis set</population>
          <units>participants who reached goal</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
                <count group_id="O2" value="202"/>
                <count group_id="O3" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="161"/>
                    <measurement group_id="O3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Score From Baseline to Week 12 in Psoriasis Symptom Diary Items Itching, Pain and Scaling in AIN457 vs Placebo</title>
        <description>The Psoriasis Symptom Diary©, a 16-item patient reported outcome (PRO) measure developed and validated in accordance with the FDA PRO Guidance (FDA Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims, 2009), demonstrated favorable psychometric properties and usefulness for treatment efficacy evaluation alongside other measures of disease severity in clinical trials for chronic plaque psoriasis.Weekly averages will be derived for each of the 16 questions of the Psoriasis Diary up to Week 12. A weekly average is the sum of the scored item over the course of the study week divided by the number of days on which the item was completed and will be set to missing if four or more daily assessments were missing of the corresponding question. The range for each question is 0 to 10 with the higher score depicting a more progressed disease state. A reduction in score from baseline shows efficacy</description>
        <time_frame>baseline to week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150mg</title>
            <description>s.c. secukinumab 150 mg injection plus a placebo secukinumab injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300mg</title>
            <description>s.c. secukinumab 300 mg injection plus a placebo secukinumab injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>AIN457A exact match Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Score From Baseline to Week 12 in Psoriasis Symptom Diary Items Itching, Pain and Scaling in AIN457 vs Placebo</title>
          <description>The Psoriasis Symptom Diary©, a 16-item patient reported outcome (PRO) measure developed and validated in accordance with the FDA PRO Guidance (FDA Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims, 2009), demonstrated favorable psychometric properties and usefulness for treatment efficacy evaluation alongside other measures of disease severity in clinical trials for chronic plaque psoriasis.Weekly averages will be derived for each of the 16 questions of the Psoriasis Diary up to Week 12. A weekly average is the sum of the scored item over the course of the study week divided by the number of days on which the item was completed and will be set to missing if four or more daily assessments were missing of the corresponding question. The range for each question is 0 to 10 with the higher score depicting a more progressed disease state. A reduction in score from baseline shows efficacy</description>
          <population>Full analysis set</population>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.92" spread="0.249"/>
                    <measurement group_id="O2" value="-4.93" spread="0.247"/>
                    <measurement group_id="O3" value="-0.54" spread="0.201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.10" spread="0.277"/>
                    <measurement group_id="O2" value="-4.48" spread="0.278"/>
                    <measurement group_id="O3" value="-0.33" spread="0.216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scaling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.89" spread="0.241"/>
                    <measurement group_id="O2" value="-4.93" spread="0.258"/>
                    <measurement group_id="O3" value="-0.42" spread="0.217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in Psoriasis Symptom Diary Items Itching, Pain and Scaling in AIN457 vs Etanercept</title>
        <description>The Psoriasis Symptom Diary©, a 16-item patient reported outcome (PRO) measure developed and validated in accordance with the FDA PRO Guidance (FDA Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims, 2009), demonstrated favorable psychometric properties and usefulness for treatment efficacy evaluation alongside other measures of disease severity in clinical trials for chronic plaque psoriasis.Weekly averages will be derived for each of the 16 questions of the Psoriasis Diary up to Week 12. A weekly average is the sum of the scored item over the course of the study week divided by the number of days on which the item was completed and will be set to missing if four or more daily assessments were missing of the corresponding question. The range for each question is 0 to 10 with the higher score depicting a more progressed disease state. A reduction in score from baseline shows efficacy</description>
        <time_frame>baseline to week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150mg</title>
            <description>s.c. secukinumab 150 mg injection plus a placebo secukinumab injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300mg</title>
            <description>s.c. secukinumab 300 mg injection plus a placebo secukinumab injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48</description>
          </group>
          <group group_id="O3">
            <title>Etanercept</title>
            <description>etanercept 50 mg twice per week until Week 12</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Psoriasis Symptom Diary Items Itching, Pain and Scaling in AIN457 vs Etanercept</title>
          <description>The Psoriasis Symptom Diary©, a 16-item patient reported outcome (PRO) measure developed and validated in accordance with the FDA PRO Guidance (FDA Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims, 2009), demonstrated favorable psychometric properties and usefulness for treatment efficacy evaluation alongside other measures of disease severity in clinical trials for chronic plaque psoriasis.Weekly averages will be derived for each of the 16 questions of the Psoriasis Diary up to Week 12. A weekly average is the sum of the scored item over the course of the study week divided by the number of days on which the item was completed and will be set to missing if four or more daily assessments were missing of the corresponding question. The range for each question is 0 to 10 with the higher score depicting a more progressed disease state. A reduction in score from baseline shows efficacy</description>
          <population>Full analysis set</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.92" spread="0.277"/>
                    <measurement group_id="O2" value="-4.93" spread="0.278"/>
                    <measurement group_id="O3" value="-3.80" spread="0.257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.10" spread="0.268"/>
                    <measurement group_id="O2" value="-4.48" spread="0.269"/>
                    <measurement group_id="O3" value="-3.48" spread="0.251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scaling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.89" spread="0.241"/>
                    <measurement group_id="O2" value="-4.93" spread="0.258"/>
                    <measurement group_id="O3" value="-3.74" spread="0.260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Developing Anti-secukinumab Antibodies</title>
        <description>Describes the number of participants tested positive for anti-secukinumab antibodies. It refers to the number of patients who had no positive values at baseline but developed them only after start of active study treatment (AIN457 or etanercept)</description>
        <time_frame>60 weeks</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150mg</title>
            <description>s.c. secukinumab 150 mg injection plus a placebo secukinumab injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300mg</title>
            <description>s.c. secukinumab 300 mg injection plus a placebo secukinumab injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48</description>
          </group>
          <group group_id="O3">
            <title>PLACEBO-150 mg AIN457</title>
            <description>Patients were on Placebo in induction phase and if they were PASI 75 non responders at week 12 were re randomized to AIN457 150 in maintenance</description>
          </group>
          <group group_id="O4">
            <title>PLACEBO-300 mg AIN457</title>
            <description>Patients were on Placebo in induction phase and if they were PASI 75 non responders at week 12 were re randomized to AIN457 300 in maintenance</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>s.c. placebo etanercept twice per week until Week 12 and s.c. placebo secukinumab (2 injections per dose) once per week for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks (at Weeks 4 and 8). Prior to receiving the Week 12 dose, all patients in the placebo group were assigned to treatment groups based on their PASI 75 response status at Week 12:</description>
          </group>
          <group group_id="O6">
            <title>Etanercept</title>
            <description>Subcutaneous (s.c.) etanercept 50 mg twice per week until Week 12, followed by s.c. etanercept 50 mg every week from Week 12 through Week 51. To maintain the blind, patients also received 2 placebo secukinumab s.c. injections once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48, except for Weeks 13, 14, and 15 where patients received an additional weekly dose (comprised of 2 s.c. injections per dose) of placebo secukinumab</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Developing Anti-secukinumab Antibodies</title>
          <description>Describes the number of participants tested positive for anti-secukinumab antibodies. It refers to the number of patients who had no positive values at baseline but developed them only after start of active study treatment (AIN457 or etanercept)</description>
          <population>Full Analysis Set</population>
          <units># participants tested positive</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="327"/>
                <count group_id="O2" value="327"/>
                <count group_id="O3" value="142"/>
                <count group_id="O4" value="142"/>
                <count group_id="O5" value="17"/>
                <count group_id="O6" value="326"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>INDUCTION-AIN457 150mg</title>
          <description>INDUCTION-AIN457 150mg</description>
        </group>
        <group group_id="E2">
          <title>INDUCTION-AIN457 300mg</title>
          <description>INDUCTION-AIN457 300mg</description>
        </group>
        <group group_id="E3">
          <title>INDUCTION-Placebo</title>
          <description>INDUCTION-Placebo</description>
        </group>
        <group group_id="E4">
          <title>INDUCTION-Etanercept</title>
          <description>INDUCTION-Etanercept</description>
        </group>
        <group group_id="E5">
          <title>ENTIRE-AIN457 150mg</title>
          <description>ENTIRE-AIN457 150mg</description>
        </group>
        <group group_id="E6">
          <title>ENTIRE-AIN457 300mg</title>
          <description>ENTIRE-AIN457 300mg</description>
        </group>
        <group group_id="E7">
          <title>ENTIRE-Any AIN457 150mg</title>
          <description>ENTIRE-Any AIN457 150mg</description>
        </group>
        <group group_id="E8">
          <title>ENTIRE-Any AIN457 300mg</title>
          <description>ENTIRE-Any AIN457 300mg</description>
        </group>
        <group group_id="E9">
          <title>ENTIRE-Placebo</title>
          <description>ENTIRE-Placebo</description>
        </group>
        <group group_id="E10">
          <title>ENTIRE-Etanercept</title>
          <description>ENTIRE-Etanercept</description>
        </group>
        <group group_id="E11">
          <title>FOLLOW UP-Any AIN457 150mg</title>
          <description>FOLLOW UP-Any AIN457 150mg</description>
        </group>
        <group group_id="E12">
          <title>FOLLOW UP-Any AIN457 300mg</title>
          <description>FOLLOW UP-Any AIN457 300mg</description>
        </group>
        <group group_id="E13">
          <title>FOLLOW UP-Placebo</title>
          <description>FOLLOW UP-Placebo</description>
        </group>
        <group group_id="E14">
          <title>FOLLOW UP-Etanercept</title>
          <description>FOLLOW UP-Etanercept</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="21" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="24" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="27" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="20" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>ARTERIOSCLEROSIS CORONARY ARTERY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>MITRAL VALVE INCOMPETENCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>BASEDOW'S DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>HYPERTHYROIDISM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>PARATHYROID GLAND ENLARGEMENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>THYROTOXIC CRISIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ANAL FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>COLITIS ULCERATIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>CROHN'S DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL FOOD IMPACTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>POLYSEROSITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ACUTE TONSILLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>ANAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>HEPATITIS B</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>PERIRECTAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>PHARYNGOTONSILLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>SUBCUTANEOUS ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>TONSILLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ALCOHOL POISONING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>CARTILAGE INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>CLAVICLE FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>HEAD INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>JOINT DISLOCATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>LACERATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>LIGAMENT RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>OVERDOSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HYPOTHYROIDISM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE RESPIRATORY DISTRESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>RADIUS FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>RIB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>TENDON INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>UPPER LIMB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>BURSITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>CHONDROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>JOINT INSTABILITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>NECK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>OSTEONECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>PSORIATIC ARTHROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>ROTATOR CUFF SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>RENAL CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>FACIAL PARESIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>SCIATICA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>VIITH NERVE PARALYSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>VITH NERVE PARALYSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>DEPRESSION SUICIDAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>DRUG ABUSE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>CALCULUS URETHRAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>RENAL COLIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>PROSTATOMEGALY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>INTERSTITIAL LUNG DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DERMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>DYSHIDROTIC ECZEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>LICHEN SCLEROSUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>PAIN OF SKIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>PSORIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>ABSTAINS FROM ALCOHOL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>ARTERIAL OCCLUSIVE DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>BEHCET'S SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE CRISIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ARTERIAL OCCLUSIVE DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="157" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="145" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="121" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="130" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="225" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="230" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="297" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="316" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="122" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="213" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="25" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="11" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="7" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="59" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CONJUNCTIVITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="8" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="14" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="30" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="34" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="36" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="38" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="22" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>TOOTHACHE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="13" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="9" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ADVERSE DRUG REACTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="16" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>INFLUENZA LIKE ILLNESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="9" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>INJECTION SITE ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="17" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="14" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="19" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="15" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="14" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="17" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="9" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>EAR INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>FOLLICULITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="14" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="13" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="8" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="18" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="8" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>IMPETIGO</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="22" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="11" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="82" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="91" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="107" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="122" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="26" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="87" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="6" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="14" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>ORAL CANDIDIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="12" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>ORAL HERPES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="9" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="13" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>RHINITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="14" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>TINEA PEDIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>TONSILLITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="12" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>TOOTH ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>TRICHOMONIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="26" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="26" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="18" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="13" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="9" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>VIRAL UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>MUSCLE RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>MUSCLE STRAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>TENDON RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERCHOLESTEROLAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>HYPERTRIGLYCERIDAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>HYPERURICAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="32" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="23" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="10" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="22" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="6" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="22" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="20" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="30" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="27" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="9" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="13" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="34" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="47" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="46" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="59" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="24" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="40" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>URETHRAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="24" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="30" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="12" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="21" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="19" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="26" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="10" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>RHINORRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ECZEMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>ERYTHRODERMIC PSORIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="12" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="21" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="17" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="11" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="16" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>PSORIASIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>SEBORRHOEIC DERMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>URTICARIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="327"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="323"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="327"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="326"/>
                <counts group_id="E7" subjects_affected="22" subjects_at_risk="469"/>
                <counts group_id="E8" subjects_affected="20" subjects_at_risk="467"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="327"/>
                <counts group_id="E10" subjects_affected="14" subjects_at_risk="323"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

